Meningococcemia

Meningococcemia is a serious infectious disease caused by the bacterium Neisseria meningitidis, which is characterized by the entry of meningococci into the bloodstream. This can lead to sepsis, which can develop very quickly and be life-threatening. Meningococcemia can present with a variety of clinical symptoms, including high fever, skin rash, hypotension, and signs of septic shock syndrome. It is important to note that the infection can progress over several hours, requiring urgent medical intervention.

History of the disease and interesting historical facts

Meningococcemia has been known to mankind since ancient times, although its full understanding was achieved only in the 20th century. The first mentions of meningococcal infection can be found in the works of ancient doctors, but the identification of the pathogen occurred in 1887, when the German microbiologist Albert Neisser isolated the bacterium Neisseria meningitidis. Epidemics of meningococcal infection were regularly recorded in various regions of the world, especially in crowded conditions, as was observed during the First and Second World Wars. In the 20th century, after the development of vaccines against meningococcus B and C, cases of meningococcemia began to decrease significantly, which indicates the successes achieved in the field of infection prevention.

Epidemiology

Meningococcemia remains a major public health problem in a number of countries. According to the World Health Organization (WHO), between 1 and 10 cases per 100,000 population are recorded annually, with so-called “meningococcal belts” in Africa where the incidence can reach 100 cases per 100,000 population. In recent decades, the geographic distribution of meningococcal disease has changed, with an increase in the incidence of meningococcal group W and Y, raising concerns among experts. Epidemics of the disease often occur in settings with limited access to health services and a lack of vaccination.

Genetic predisposition to this disease

Research shows that there is a certain genetic predisposition to meningococcemia. In particular, mutations in genes responsible for the immune response can increase the risk of severe infection. For example, a deficiency of components of the complement system (C5-C9) involved in the opsonization of bacteria can lead to increased susceptibility to meningococci. In addition, research shows that polymorphisms in genes such as IL-10 and TNF-α can affect the level of inflammatory response, which is also associated with the severity of the disease.

Risk factors for the development of this disease

Risk factors that contribute to the development of meningococcemia include:

• Incomplete course of vaccination against meningococcal infections.
• Predisposition to certain diseases, such as immunodeficiencies and chronic pathologies.
• A tendency to be in large crowds, such as in educational institutions or military camps.
• Exposure of the body to factors such as smoking and alcohol, which can weaken the immune response.
• Periods of intense stress or hypothermia, which can also reduce the body's defenses.

Diagnosis of this disease

Diagnosis of meningococcemia involves several key steps, beginning with a clinical assessment of symptoms. Key symptoms may include:

• A sudden increase in body temperature.
• Severe headaches and vomiting.
• A rash that may not disappear when pressed.
• Problems with consciousness, including confusion and lethargy.
• Symptoms of meningeal irritation, such as positive Kernig's and Brudzinski's signs.

Laboratory tests are an essential part of the diagnosis. It is important to test the blood for meningococci, and to examine the cerebrospinal fluid to evaluate the possible presence of bacteria. Radiological tests, such as CT or MRI, may be needed to rule out other diseases. Differential diagnosis includes thinking about other causes of acute sepsis syndrome, such as viral infections or other bacterial septicemia.

Treatment

Treatment of meningococcemia should be started immediately when the disease is suspected. The main focus is on maintaining vital functions of the body and fighting infection:

• General treatment includes intensive care with monitoring of hemodynamic parameters.
• Antibiotic therapy - the need for rapid administration of antibiotics is critical; penicillins and cephalosporins are preferred.
• Symptomatic treatment may include the use of antipyretic and anti-inflammatory drugs.
• If necessary, surgical treatment may be required to remove necrotic tissue or inadequate drainage.
• Immune-boosting drugs may be added depending on the patient's condition.

List of medications used to treat this disease

The following drugs are used in the treatment of meningococcemia:

• Penicillin.
• Ceftriaxone.
• Azithromycin.
• Vancomycin (if resistance is suspected).
• Nonsteroidal anti-inflammatory drugs (eg, Ibuprofen)

Disease monitoring

Monitoring for meningococcemia is an important part of patient care. Monitoring steps include:

• Regular assessment of inflammatory markers such as C-reactive protein and complete blood count.
• Monitor vital signs including blood pressure, heart rate and oxygen levels.
• Assessment of neurological status to identify possible complications.
• The prognosis of the disease depends on the speed of treatment and the severity of the clinical picture; possible complications may include deafness, amputation of limbs, or death.

Age-related features of the disease

Meningococcemia may present differently depending on the age group. In newborns and infants, symptoms may be non-specific and difficult to diagnose. In children and adolescents, the disease may present more vividly with severe symptoms. Older adults are more likely to develop complications and mortality due to underlying medical conditions and decreased immune defense.

Questions and Answers

• What causes meningococcemia? Meningococcemia is caused by the bacterium Neisseria meningitidis, which can enter the bloodstream from the nasopharynx.
• What are the main symptoms of the disease? The main symptoms include high fever, severe headaches, rash and confusion.
• What is the mortality rate for meningococcemia? In the absence of timely treatment, the mortality rate can be 10-15% even if all measures are taken, and in the case of AIDS and weakened immunity, it is significantly higher.
• Can meningococcemia be prevented? Yes, vaccination against meningococcal infection is an effective method of prevention.
• What is the antibiotic of choice for the treatment of meningococcemia? Penicillin is often considered the drug of choice, but cephalosporins may be used in some cases.